Clinical efficacy and immune mechanism of Bushen Yifei Decoction in the treatment of stable chronic obstructive pulmonary disease

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) The patients who meet the criteria of moderate and severe COPD in western medicine and meet the deficiency of both lung and kidney syndrome in traditional Chinese medicine were screened out;
•(2) The age of the patients ranged from 40 to 80 years old;
•(3) Men and women are not limited;
•(4) Did not take any traditional Chinese medicine within 30 days;
•(5) Inform patients of the research information, so that patients get the right to know, and voluntarily sign the relevant documents.

•(1) Diseases with airflow limitation caused by special reasons, such as silicosis, interstitial lung disease, lung tumor, etc;
•(2) The patients with active pulmonary tuberculosis, bronchiectasis, asthma, pleural effusion, pneumothorax and pulmonary embolism disease;
•(3) Patients with severe heart, liver and kidney diseases, of which severe kidney disease mainly refers to kidney transplantation and dialysis; liver disease mainly includes varicose bleeding, portal hypertension and liver cirrhosis; heart diseases mainly include acute myocardial infarction, etc;
•(4) Dementia or weak or no cognitive ability;
•(5) Patients with neurological diseases that affect respiratory function;
•(6) Patients with drug allergy and patients undergoing other clinical trials.

发起方

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine